 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth,topical |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C22H14F3NO5 |
| Molar mass | 429.351 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Funapide (INN; former developmental codesTV-45070 andXEN402) is a novelanalgesic under development byXenon Pharmaceuticals (formerly in partnership withTeva Pharmaceutical Industries) for the treatment of a variety ofchronic pain conditions, includingosteoarthritis,neuropathic pain,postherpetic neuralgia, anderythromelalgia, as well asdental pain.[1][2][3][4] It acts as asmall-moleculeNav1.7 andNav1.8voltage-gated sodium channelblocker.[1][2][4] Funapide was evaluated in humans in bothoral andtopical formulations, and as of July 2014, had reachedphase IIbclinical trials.[1][3]Development of the drug was discontinued in 2022.[5]
